- In February, 2025 reports FERMENZA, a postbiotic gel rich in gallic and ellagic acids, demonstrated ~81% in vitro inhibition of Malassezia folliculitis and ~85% inhibition against P. acnes—comparable to clindamycin 2%
- In June 2019, Galderma granted U.S. patent for an anti-inflammatory compound targeting folliculitis. Galderma obtained U.S. patent 10,328,094 for a topical avermectin-based compound—such as ivermectin—intended to prevent folliculitis, particularly in cancer patients undergoing treatment.
